Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 226pembrolizumab 218Carboplatin 174Biopsy 164Cisplatin 157Nivolumab 155Cyclophosphamide 139Radiotherapy 121Paclitaxel 120Gemcitabine 113durvalumab 90Bevacizumab 89Dexamethasone 82Rituximab 81Oxaliplatin 77venetoclax 73atezolizumab 70Doxorubicin 70Docetaxel 66Radiosurgery 65Fluorouracil 65Ipilimumab 64Capecitabine 64Etoposide 62Radiation 59Prednisone 59Cytarabine 59Lenalidomide 56fludarabine 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × cc-486 × 90 days × Clear all
NCT05413018 2026-04-28

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Bristol-Myers Squibb

Phase 2 Active not recruiting
34 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡